Accessibility Menu
Biotricity logo

Biotricity(OTC) BTCY

Current Price$0.12
Market Cap$2.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-99%
5 Year-97%
1 Year-77%
1 Month-10%
Biotricity last closing stock price
MetricPriceDate
Last closeUSD 0.122026-07-22
Biotricity stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.37%USD 0.122026-07-15
1 month-9.75%USD 0.132026-06-22
3 month-50.11%USD 0.232026-04-23
Year to date-60.95%USD 0.302025-12-31
1 year-77.03%USD 0.512025-07-22
3 year-96.73%USD 3.582021-08-25
5 year-96.75%USD 3.602021-07-23
Since inception-99.26%USD 15.902016-02-18

Biotricity Financials at a Glance

Market Cap

$2.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$16.00M

Net Income (TTM)

-$2.40M

EPS (TTM)

-$0.11

P/E Ratio

-1.02

Dividend

$0.00

Beta (Volatility)

1.70 (High)

Price

$0.12

Volume

73,479

Open

$0.11

Previous Close

$0.12

Daily Range

$0.11 - $0.12

52-Week Range

$0.09 - $0.75

Estimated Earnings Date

Aug 13, 2026

BTCY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biotricity

Biotricity helps doctors and patients track heart health remotely. Its devices monitor heart rhythms and send data to healthcare providers. This supports early detection and ongoing care for people with heart conditions.

Gadgets That Listen to Your Heart

  • Remote cardiac monitoring (87% of revenue for the three months ended June 30, 2025): Devices and software that track heart activity for doctors and clinics.
  • Device sales (13% of revenue for the three months ended June 30, 2025): Physical heart monitoring devices sold to medical centers and physicians.
  • Bioflux: Mobile heart monitor and analysis software for patients needing continuous heart rhythm checks.
  • Biocore: Wearable device for lower-risk patients, including a cellular version for remote use.
  • Bioheart: Consumer heart monitor for personal use, offering continuous heart tracking.
  • Biocare app: App for managing chronic care and sharing health data with providers.

Growth Moves: Not Just a Pulse, a Pattern

  • Launched Bioflux and Biocore devices, expanding product line since 2018 IPO.
  • Introduced Biocore Pro in October 2023 and Biocare app in March 2023 to reach new patient groups.
  • Secured NIH grant in 2022 for AI-powered heart monitoring research.
  • Expanded sales force and coverage to 31 U.S. states by June 2025.

Why Biotricity Gets Noticed

Biotricity focuses on recurring technology fees, not just device sales, creating steady revenue. Its proprietary software uses artificial intelligence to analyze billions of heartbeats. The company’s U.S.-centered distribution and cloud partnerships support rapid product updates and broad reach.

Five Things You Need to Know

  • Revenue was $3.87 million in Q2 2025, up 21% year-over-year.
  • Technology fees made up 87% of total revenue in Q2 2025.
  • Gross margin reached 80.5% in Q2 2025, up from 73.8% last year.
  • First positive operating income of $0.28 million in Q2 2025.
  • Working capital deficiency was $16.66 million as of June 30, 2025.

Bottom Line

Biotricity has shifted from device sales to recurring technology fees and AI-driven services. The company faces financial challenges but continues to expand its product line and market reach.

AI Generated • Apr 16, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

46

CEO

Waqaas Al-Siddiq, PhD, MBA

Website

www.biotricity.com

Headquarters

Redwood City, CA 94065, US

BTCY Financials

Key Financial Metrics (TTM)

Gross Margin

81.09%

Operating Margin

0.91%

Net Income Margin

-25.99%

Return on Equity

12.39%

Return on Capital

N/A

Return on Assets

-62.29%

Earnings Yield

-98.04%

Dividend Yield

0.00%

Payout Ratio

-0.60%

Stock Overview

Market Cap

$2.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

20.24M

Volume

73.48K

Avg. Volume

70.74K

Financials (TTM)

Gross Profit

$12.95M

Operating Income

$1.69M

EBITDA

$1.71M

Operating Cash Flow

-$718.96K

Capital Expenditure

$5.00

Free Cash Flow

-$718.96K

Cash & ST Invst.

$149.79K

Total Debt

$27.06M

Biotricity Performance Analysis

Biotricity annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 9,639,05726.0%
20242024-03-31USD 12,063,34525.2%
20252025-03-31USD 13,790,29414.3%
20262026-03-31USD 15,998,23916.0%
Biotricity sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-304.6%
Q22025-09-300.3%
Q32025-12-312.6%
Q42026-03-316.6%
Biotricity annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -2.26-43.5%
20242024-03-31USD -1.66-26.4%
20252025-03-31USD -0.55-66.6%
20262026-03-31USD -0.11-79.3%
Biotricity sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-3067.5%
Q22025-09-308.4%
Q32025-12-31-58.2%
Q42026-03-3162.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$4.25M

+14.8%

Gross Profit

$3.40M

+14.1%

Gross Margin

79.97%

N/A

Market Cap

$2.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$51.53K

N/A

Employees

46

N/A

Net Income

-$324.18K

+83.3%

EBITDA

$818.26K

+193.2%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$149.79K

-59.0%

Total Debt

$27.06M

+3.7%

Accounts Receivable

$2.93M

+7.9%

Inventory

$1.34M

-13.8%

Long Term Debt

$870.80K

-93.6%

Short Term Debt

$26.19M

+108.7%

Return on Assets

-62.29%

N/A

Return on Invested Capital

-0.46%

N/A

Free Cash Flow

-$20.91K

+94.8%

Operating Cash Flow

-$20.91K

+94.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMMVFImmunovia AB
$0.02+0.00%
ALRTFALR Technologies Inc.
$0.02+0.00%
ASAPFAurora Spine Corporation
$0.16+5.96%
UEECUnited Health Products, Inc.
$0.05-2.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%

Questions About BTCY

What is the current price of Biotricity?

Biotricity is trading at $0.12 per share.

What is the 52-week range for Biotricity?

Over the past 52 weeks, Biotricity has traded between $0.09 and $0.75.

How much debt does Biotricity have?

As of the most recent reporting period, Biotricity reported total debt of $27.06M.

How much cash does Biotricity have on hand?

Biotricity reported $149.79K in cash and cash equivalents in its most recent financial results.

What is Biotricity’s dividend yield?

Biotricity does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services